表紙
市場調查報告書

市場焦點:神經病變性疼痛

Market Spotlight: Neuropathic Pain

出版商 Datamonitor Healthcare 商品編碼 573564
出版日期 內容資訊 英文 40 Pages
商品交期: 最快1-2個工作天內
價格
市場焦點:神經病變性疼痛 Market Spotlight: Neuropathic Pain
出版日期: 2019年10月25日內容資訊: 英文 40 Pages
簡介

本報告提供神經病變性疼痛市場相關調查分析,提供主要開發平台·上市藥,臨床試驗,法規趨勢,專利資訊,罹患率的10年預測,許可證·收購交易,收益預測等系統性資訊。

要點

疾病的背景

  • 亞型

治療

  • 抗憂鬱症藥
  • 抗癲癇藥
  • 大麻素
  • 類鴉片物質
  • 局部療法

流行病學

開發平台藥物

上市藥

  • 核准:各國

法規趨勢

許可證·資產收購交易

母專利

商機

臨床試驗形勢

  • 贊助商:各狀況
  • 贊助商:不同階段

參考文獻

  • 處方箋資訊

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0179877

This Market Spotlight report covers the neuropathic pain market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and asset acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

Datamonitor Healthcare estimates that in 2017, there were 425.2 million prevalent cases of neuropathic pain in adults aged 20 years and older worldwide, and forecasts that number to increase to 476.2 million prevalent cases by

2026. Asia is estimated to have had the largest number of prevalent cases in 2017, driven by population size, while having the lowest prevalence proportion (98.1 million cases; 3.2%).

The marketed drugs in the neuropathic pain space target sodium channels, voltage-gated calcium channels, and transient receptor potential vanilloid receptor

1. These drugs are administered via the oral route, except for Qutenza, which is available as a topical formulation.

The majority of industry-sponsored drugs in active clinical development for neuropathic pain are in Phase I. Therapies in development for neuropathic pain focus on a wide variety of targets. The majority of pipeline drugs in early- and mid-stage development are administered orally, with the remainder being intravenous, intramuscular, intrathecal, intradermal, subcutaneous, and topical formulations.

High-impact upcoming events for drugs in the neuropathic pain space comprise topline Phase Iia trial results for AP-325 and topline Phase II trial results for Dysport.

The overall likelihood of approval of a Phase I neuropathic pain asset is 0.8%, and the average probability a drug advances from Phase III is 33.3%. Drugs, on average, take 8.9 years from Phase I to approval, compared to 9.8 years in the overall neurology space.

There have been 30 licensing and asset acquisition deals involving neuropathic pain drugs during 2014-19, eight of which occurred in

2015. The exclusive licensing agreement in 2015 between Depomed and Janssen for the acquisition of the US rights to Nucynta, for $1.05bn, was the largest deal during the period.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials have been in the early and mid-phases of development, with 69% of trials in Phase I-II, and only 31% in Phase III-IV.

The US has a substantial lead in the number of neuropathic pain clinical trials globally. The UK leads the major EU markets, while Japan has the top spot in Asia.

Clinical trial activity in the neuropathic pain space is dominated by completed trials. Pfizer has the highest number of completed clinical trials for neuropathic pain, with 231 trials.

Pfizer leads industry sponsors with by far the highest overall number of clinical trials for neuropathic pain, followed by Allergan

TABLE OF CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Subtypes

TREATMENT

  • Antidepressants
  • Antiepileptics
  • Cannabinoids
  • Opioids
  • Topical or focal therapies

EPIDEMIOLOGY

  • Limitations of neuropathic pain prevalence estimates

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • VX-150 for Neuropathic Pain (December 18, 2018)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Abbott Wins FDA Approval For 'Low Dose' Non-Rechargeable Spinal Cord Stimulator
  • Lyrica Generics Likely Delayed By A Pfizer Labeling Supplement

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Eli Lilly licenses exclusive rights to develop and sell CNTX0290 from Centrexion

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in prevalent cases of neuropathic pain, 2017-26
  • Figure 2: Overview of pipeline drugs for neuropathic pain in the US
  • Figure 3: Pipeline drugs for neuropathic pain, by company
  • Figure 4: Pipeline drugs for neuropathic pain, by drug type
  • Figure 5: Pipeline drugs for neuropathic pain, by drug classification
  • Figure 6: VX-150 for Neuropathic Pain (December 18, 2018): Phase II - Small Fiber Neuropathy
  • Figure 7: Key upcoming events in neuropathic pain
  • Figure 8: Probability of success in the neuropathic pain pipeline
  • Figure 9: Licensing and asset acquisition deals in neuropathic pain, 2014-19
  • Figure 10: Parent patents in neuropathic pain
  • Figure 11: Clinical trials in neuropathic pain
  • Figure 12: Top 10 drugs for clinical trials in neuropathic pain
  • Figure 13: Top 10 companies for clinical trials in neuropathic pain
  • Figure 14: Trial locations in neuropathic pain
  • Figure 15: Neuropathic pain trials status
  • Figure 16: Neuropathic pain trials sponsors, by phase

LIST OF TABLES

  • Table 1: Prevalence methodology
  • Table 2: Prevalent cases of neuropathic pain, 2017-26
  • Table 3: Prevalence proportions of neuropathic pain, 2017-26
  • Table 4: Marketed drugs for neuropathic pain
  • Table 5: Pipeline drugs for neuropathic pain in the US
  • Table 6: VX-150 for Neuropathic Pain (December 18, 2018)
  • Table 7: Historical global sales, by drug ($m), 2014-18
  • Table 8: Forecasted global sales, by drug ($m), 2019-23